RxDoctor Payments Data

Aaron Heiar, DO

Family Medicine · Iowa Falls, IANPI 1558321075

Payments from drug & device makers

$526in general payments, 2019–2025

Across 9 payments — averaging $58.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$149
  • Sunovion Pharmaceuticals Inc.$108
  • Astellas Pharma US Inc$100
  • Sanofi$46
  • Amgen$44
  • Boehringer Ingelheim$43
  • plus $36 from 1 others

What the payments were for

  • Food & beverage$42681%
  • Education$10019%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$526 in reported general payments places this provider in the 70th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$296,662
Medicare patients
343
Services billed
8,401

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide110$111,705
EliquisApixaban125$63,856
XifaxanRifaximin40$62,350
JardianceEmpagliflozin56$35,976
XareltoRivaroxaban64$33,223
TrulicityDulaglutide22$21,885
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$16,586
Spiriva HandihalerTiotropium Bromide15$8,758
MyrbetriqMirabegron13$6,116
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$5,044
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$4,881
Atorvastatin Calcium494$4,853
Mycophenolic AcidMycophenolate Sodium12$4,007
Fentanyl67$3,945
Tacrolimus13$3,459

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat$43$41,02067 claims
GSKTrelegy Ellipta$36$16,58625 claims
Astellas Pharma US IncMyrbetriq$100$6,11613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Iowa Falls

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →